{"id":"adt-for-9-months-and-arta-for-6-months","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Hot flashes"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Muscle weakness"},{"rate":"10-30%","effect":"Bone loss"},{"rate":"5-20%","effect":"Infertility"}]},"_chembl":{"chemblId":"CHEMBL496957","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ADT is typically used to treat hormone-sensitive cancers, such as prostate cancer, by reducing the levels of androgens in the body. ARTA, on the other hand, targets the androgen receptor itself, preventing cancer cells from responding to androgens. This dual approach can be effective in treating hormone-sensitive cancers.","oneSentence":"Androgen deprivation therapy (ADT) involves blocking the production of androgens, such as testosterone, which fuel the growth of prostate cancer cells. Androgen receptor signaling inhibitor (ARTA) works by blocking the androgen receptor, preventing cancer cells from receiving the signals they need to grow and multiply.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:56.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"},{"name":"Metastatic prostate cancer"}]},"trialDetails":[{"nctId":"NCT06818682","phase":"PHASE2","title":"Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2025-02-17","conditions":"Prostate Carcinoma","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ADT for 9 months and ARTA for 6 months","genericName":"ADT for 9 months and ARTA for 6 months","companyName":"Tata Memorial Centre","companyId":"tata-memorial-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Androgen deprivation therapy (ADT) involves blocking the production of androgens, such as testosterone, which fuel the growth of prostate cancer cells. Androgen receptor signaling inhibitor (ARTA) works by blocking the androgen receptor, preventing cancer cells from receiving the signals they need to grow and multiply. Used for Prostate cancer, Metastatic prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}